CytoSorbents Q2 2026 earnings: Margins improve despite flat revenue

CytoSorbents (NASDAQ: CTSO) reported Q2 2026 revenue of $9.63 million, essentially flat versus $9.62 million a year earlier, while diluted EPS swung to a loss of $0.07 from earnings of $0.03. Gross margin improved to 73%, and the operating loss narrowed 27%, but foreign-currency effects pushed the company to a $4.4 million GAAP net loss.

Core results

Flat revenue masked an improvement in underlying operating economics. Gross profit increased as manufacturing optimization, sourcing improvements and production efficiencies lifted gross margin by two percentage points, while lower selling, general and administrative expense helped reduce the operating loss.

The comparison between GAAP and adjusted results is important because Q2 2025 included a substantial foreign-currency gain, while Q2 2026 included a loss.

Adjusted results exclude items including foreign-currency effects, non-cash stock compensation and restructuring charges, according to the company’s non-GAAP definitions.

Business and channel performance

Growth in distributor and strategic-partner territories, together with direct markets outside Germany, offset weaker German sales. Germany remained the principal commercial drag after restructuring left the company with a smaller sales force.

CytoSorbents plans to add three to five sales representatives through early 2027 to restore full coverage in Germany. Management also cited increasing adoption of the PuriFi pump platform and HotSwap technology, although it did not quantify their revenue contribution.

Foreign exchange masked better operating economics

The company’s operating performance improved even though its GAAP bottom line deteriorated. Operating expenses declined to $9.69 million from $10.43 million, led by selling, general and administrative expense falling to $7.96 million from $9.17 million. Research and development expense increased to $1.45 million from $1.26 million, and the quarter included $270,000 of restructuring expense.

Below the operating line, foreign-currency transactions shifted from a $6.18 million gain in Q2 2025 to a $911,000 loss in Q2 2026. That approximately $7.1 million reversal more than offset the improvement in gross profit and operating expenses. Net interest expense also increased to $868,000 from $616,000.

The narrower adjusted net and adjusted EBITDA losses therefore provide a clearer indication of the cost and manufacturing progress achieved during the quarter, while the GAAP result illustrates the continuing volatility created by foreign exchange.

Cash flow and balance sheet

Cash, cash equivalents and restricted cash totaled $5.94 million at June 30, 2026, down from approximately $6.3 million at March 31. Cash and cash equivalents excluding restricted cash were $4.41 million.

The company reported Q2 total cash burn of $0.4 million, including approximately $0.2 million of restructuring payments. Excluding those payments, management placed operating cash burn at roughly $0.2 million. This quarterly management metric should be distinguished from the cash flow statement, which showed $1.75 million of net cash used in operating activities for the six months ended June 30, down from $4.98 million in the prior-year period.

Working-capital reductions supported cash flow. Inventory declined to $3.69 million from $5.28 million at the end of 2025, while accounts receivable fell to $6.79 million from $7.55 million.

Liquidity nevertheless remains constrained. Current liabilities reached $24.02 million compared with $15.74 million of current assets. Current maturities of long-term debt were $14.15 million, while long-term debt excluding the current portion was $3.09 million. Stockholders’ equity also moved to a $751,000 deficit from positive equity of $5.90 million at December 31, 2025.

Management said it remained on track toward its objective of operating cash flow breakeven in the second half of 2026, but the company had not reached that milestone by quarter-end.

DrugSorb-ATR and regulatory milestones

CytoSorbents had two FDA pre-submission meetings scheduled for August 2026. The first was intended to address additional mechanistic data requested for the DrugSorb-ATR Brilinta program. After agreeing on the testing protocol, the company expects to complete the work and submit a new De Novo application in early 2027, supported by additional real-world analyses covering four times as many coronary artery bypass graft patients as the original STAR-T trial.

The second meeting was designed to discuss a possible parallel De Novo submission for patients taking the direct oral anticoagulants apixaban and rivaroxaban. DrugSorb-ATR has not received marketing authorization in the United States or Canada, making the timing and requirements of these regulatory pathways important uncertainties. Management estimates an initial U.S. and Canadian market opportunity of $500 million to $1 billion if future approval is obtained.

For HemoDefend-BGA, the company reported constructive FDA feedback in July 2026 regarding the anticipated clinical pathway. It is also discussing potential non-dilutive clinical-development funding with U.S. government agencies, but did not announce a funding commitment or commercialization timeline.

Recent insider transactions

Transaction-level insider data lists two purchases dated June 15, 2026. These entries show the individuals, prices and reported transaction values but do not support conclusions about management’s broader outlook.

A separate six-month aggregate in the provided dataset showed zero purchases, conflicting with these transaction-level entries. The underlying regulatory filings would therefore be the appropriate source for verification.

Risks investors should watch

• Germany execution: A 24% sales decline in Germany offset growth elsewhere. Restoring growth depends partly on recruiting and successfully deploying three to five additional representatives.
• Liquidity and debt maturities: Unrestricted cash was $4.41 million, current liabilities exceeded current assets and $14.15 million of debt was classified as current. Continued losses or delays in reaching cash flow breakeven could increase financing pressure.
• Regulatory uncertainty: DrugSorb-ATR remains unapproved in the United States and Canada. The FDA requested additional mechanistic data, and the planned early-2027 De Novo submission depends on finalizing and completing the required testing.
• Earnings volatility: CytoSorbents remains unprofitable on both operating and adjusted EBITDA bases. Foreign-currency movements can also produce substantial differences between operating progress and GAAP net results.
• Listing compliance: Management said it intends to regain compliance with Nasdaq listing requirements, indicating that compliance remained an outstanding issue at the time of the update.

Summary

CytoSorbents’ Q2 2026 revenue remained flat because growth outside Germany was offset by a sharp decline in its largest direct market. Manufacturing improvements and tighter costs lifted gross margin and narrowed operating and adjusted losses, while foreign-currency effects drove the GAAP loss. The next major points to monitor are German sales-force rebuilding, available liquidity and debt maturities, progress toward second-half operating cash flow breakeven, and the FDA pathway for DrugSorb-ATR.